Global Single-Domain Antibody Therapeutics Market Growth 2026-2032
The global Single-Domain Antibody Therapeutics market size is predicted to grow from US$ 491 million in 2025 to US$ 1119 million in 2032; it is expected to grow at a CAGR of 12.3% from 2026 to 2032.
Single-domain antibody therapeutics are biologic treatments developed around a single antibody variable domain, including VHH, human VH, human VL, and VNAR domains. These domains can be linked, fused, conjugated, or assembled into monovalent, bivalent, multivalent, multispecific, Fc-fusion, and albumin-binding half-life-extended formats. Major therapeutic applications include hematological disorders, autoimmune and inflammatory diseases, oncology, respiratory diseases, and infectious diseases. Representative commercialized products include Sanofi's Cablivi, Taisho Pharmaceutical's Nanozora, and Envafolimab developed by Alphamab Oncology, while a growing number of multivalent, multispecific, and inhaled single-domain antibody candidates remain in clinical development. Key upstream inputs include antibody discovery and display libraries, engineered production cell lines, culture media, feeds, single-use bioreactor consumables, chromatography resins, ultrafiltration membranes, buffers, linkers, sterile filling components, vials or prefilled syringes, and cold-chain packaging materials. Downstream users and treatment settings include pharmaceutical and biotechnology companies, hospitals, specialty treatment centers, and clinical departments specializing in hematology, rheumatology, oncology, and respiratory medicine. Based on commercial drug shipments at ex-factory prices, global nominal production capacity in 2025 is estimated at approximately 1.25 million units, with actual sales volume of around 728,000 units, an average ex-factory price of approximately USD 690 per unit, and an overall industry gross margin of about 70%?85%.
The single-domain antibody therapeutics market has progressed from early platform validation toward a stage where commercial products and clinical pipelines coexist. Approved therapies have established clinical use in hematological disorders, autoimmune diseases, and oncology, although the total number of marketed products remains considerably smaller than that of conventional full-length monoclonal antibodies. The competitive landscape consists of a limited number of mature platform owners and a broader group of clinical-stage biotechnology companies. Leading participants benefit from antibody discovery capabilities, molecular engineering expertise, clinical development experience, and global commercialization infrastructure. Companies in China, the United States, Europe, and Japan are also developing differentiated strategies in subcutaneous administration, inhaled delivery, multispecific formats, and local treatment. Future development is expected to move further toward multivalent, multispecific, half-life-extended, and tissue-targeted formats. The small size and relatively simple structure of single-domain antibodies make them suitable for linking multiple binding domains, albumin-binding modules, Fc regions, and functional effector units within one molecule. This enables developers to adjust potency, pharmacokinetics, tissue distribution, and dosing frequency. Advances in protein engineering may expand the modality from single-target blockade to dual-pathway inhibition, receptor agonism, immune-cell engagement, and targeted payload delivery. Inhaled, local, and mucosal administration may also become increasingly important, particularly in respiratory, ophthalmic, gastrointestinal, and localized inflammatory diseases. Market growth is being supported by unmet medical needs, the tissue penetration limitations of conventional antibodies, rising demand for multispecific biologics, and the development of more convenient administration routes. Single-domain antibodies can potentially access tissue compartments that are less accessible to full-length antibodies and may be produced through microbial or mammalian expression systems, providing flexibility for concentrated formulations, subcutaneous dosing, and local delivery. Acquisitions, licensing agreements, and co-development partnerships involving large pharmaceutical companies are also accelerating clinical development and global registration. As more candidates reach late-stage trials and demonstrate clear therapeutic differentiation, the modality may expand further across autoimmune disease, inflammation, oncology, respiratory disease, and rare disease treatment. The main barriers include short natural half-life, rapid renal clearance, potential immunogenicity associated with certain animal-derived sequences, and the increasing complexity of multidomain molecules. Developers often use albumin-binding domains, Fc fusion, or other half-life-extension technologies to improve systemic exposure, but these modifications may reduce some of the size and tissue penetration advantages of standalone domains. Multivalent and multispecific formats can also create challenges involving aggregation, stability, expression yield, analytical characterization, and batch consistency. From a commercial perspective, single-domain therapeutics compete with conventional monoclonal antibodies, biosimilars, small-molecule drugs, and alternative antibody formats. Broader adoption will therefore depend on demonstrating clear advantages in efficacy, safety, administration convenience, or treatment economics.
LP Information, Inc. (LPI) ' newest research report, the ?Single-Domain Antibody Therapeutics Industry Forecast? looks at past sales and reviews total world Single-Domain Antibody Therapeutics sales in 2025, providing a comprehensive analysis by region and market sector of projected Single-Domain Antibody Therapeutics sales for 2026 through 2032. With Single-Domain Antibody Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Single-Domain Antibody Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Single-Domain Antibody Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Single-Domain Antibody Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Single-Domain Antibody Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Single-Domain Antibody Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Single-Domain Antibody Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Single-Domain Antibody Therapeutics market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Single-Domain Antibody Therapeutics market?
What factors are driving Single-Domain Antibody Therapeutics market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Single-Domain Antibody Therapeutics market opportunities vary by end market size?
How does Single-Domain Antibody Therapeutics break out by Type, by Application?
Single-domain antibody therapeutics are biologic treatments developed around a single antibody variable domain, including VHH, human VH, human VL, and VNAR domains. These domains can be linked, fused, conjugated, or assembled into monovalent, bivalent, multivalent, multispecific, Fc-fusion, and albumin-binding half-life-extended formats. Major therapeutic applications include hematological disorders, autoimmune and inflammatory diseases, oncology, respiratory diseases, and infectious diseases. Representative commercialized products include Sanofi's Cablivi, Taisho Pharmaceutical's Nanozora, and Envafolimab developed by Alphamab Oncology, while a growing number of multivalent, multispecific, and inhaled single-domain antibody candidates remain in clinical development. Key upstream inputs include antibody discovery and display libraries, engineered production cell lines, culture media, feeds, single-use bioreactor consumables, chromatography resins, ultrafiltration membranes, buffers, linkers, sterile filling components, vials or prefilled syringes, and cold-chain packaging materials. Downstream users and treatment settings include pharmaceutical and biotechnology companies, hospitals, specialty treatment centers, and clinical departments specializing in hematology, rheumatology, oncology, and respiratory medicine. Based on commercial drug shipments at ex-factory prices, global nominal production capacity in 2025 is estimated at approximately 1.25 million units, with actual sales volume of around 728,000 units, an average ex-factory price of approximately USD 690 per unit, and an overall industry gross margin of about 70%?85%.
The single-domain antibody therapeutics market has progressed from early platform validation toward a stage where commercial products and clinical pipelines coexist. Approved therapies have established clinical use in hematological disorders, autoimmune diseases, and oncology, although the total number of marketed products remains considerably smaller than that of conventional full-length monoclonal antibodies. The competitive landscape consists of a limited number of mature platform owners and a broader group of clinical-stage biotechnology companies. Leading participants benefit from antibody discovery capabilities, molecular engineering expertise, clinical development experience, and global commercialization infrastructure. Companies in China, the United States, Europe, and Japan are also developing differentiated strategies in subcutaneous administration, inhaled delivery, multispecific formats, and local treatment. Future development is expected to move further toward multivalent, multispecific, half-life-extended, and tissue-targeted formats. The small size and relatively simple structure of single-domain antibodies make them suitable for linking multiple binding domains, albumin-binding modules, Fc regions, and functional effector units within one molecule. This enables developers to adjust potency, pharmacokinetics, tissue distribution, and dosing frequency. Advances in protein engineering may expand the modality from single-target blockade to dual-pathway inhibition, receptor agonism, immune-cell engagement, and targeted payload delivery. Inhaled, local, and mucosal administration may also become increasingly important, particularly in respiratory, ophthalmic, gastrointestinal, and localized inflammatory diseases. Market growth is being supported by unmet medical needs, the tissue penetration limitations of conventional antibodies, rising demand for multispecific biologics, and the development of more convenient administration routes. Single-domain antibodies can potentially access tissue compartments that are less accessible to full-length antibodies and may be produced through microbial or mammalian expression systems, providing flexibility for concentrated formulations, subcutaneous dosing, and local delivery. Acquisitions, licensing agreements, and co-development partnerships involving large pharmaceutical companies are also accelerating clinical development and global registration. As more candidates reach late-stage trials and demonstrate clear therapeutic differentiation, the modality may expand further across autoimmune disease, inflammation, oncology, respiratory disease, and rare disease treatment. The main barriers include short natural half-life, rapid renal clearance, potential immunogenicity associated with certain animal-derived sequences, and the increasing complexity of multidomain molecules. Developers often use albumin-binding domains, Fc fusion, or other half-life-extension technologies to improve systemic exposure, but these modifications may reduce some of the size and tissue penetration advantages of standalone domains. Multivalent and multispecific formats can also create challenges involving aggregation, stability, expression yield, analytical characterization, and batch consistency. From a commercial perspective, single-domain therapeutics compete with conventional monoclonal antibodies, biosimilars, small-molecule drugs, and alternative antibody formats. Broader adoption will therefore depend on demonstrating clear advantages in efficacy, safety, administration convenience, or treatment economics.
LP Information, Inc. (LPI) ' newest research report, the ?Single-Domain Antibody Therapeutics Industry Forecast? looks at past sales and reviews total world Single-Domain Antibody Therapeutics sales in 2025, providing a comprehensive analysis by region and market sector of projected Single-Domain Antibody Therapeutics sales for 2026 through 2032. With Single-Domain Antibody Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Single-Domain Antibody Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Single-Domain Antibody Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Single-Domain Antibody Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Single-Domain Antibody Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Single-Domain Antibody Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Single-Domain Antibody Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Single-Domain Antibody Therapeutics market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Cablivi
- Nanozora
- Envafolimab
- Subcutaneous Injection
- Intravenous Injection
- Other
- Online Sales
- Offline Sales
- Hospital
- Clinic
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sanofi
- Taisho Pharmaceutical
- Alphamab Oncology
What is the 10-year outlook for the global Single-Domain Antibody Therapeutics market?
What factors are driving Single-Domain Antibody Therapeutics market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Single-Domain Antibody Therapeutics market opportunities vary by end market size?
How does Single-Domain Antibody Therapeutics break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Single-Domain Antibody Therapeutics Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Single-Domain Antibody Therapeutics by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Single-Domain Antibody Therapeutics by Country/Region, 2021, 2025 & 2032
2.2 Single-Domain Antibody Therapeutics Segment by Type
2.2.1 Cablivi
2.2.2 Nanozora
2.2.3 Envafolimab
2.2.4 Single-Domain Antibody Therapeutics Sales by Type
2.2.4.1 Global Single-Domain Antibody Therapeutics Sales Market Share by Type (2021-2026)
2.2.4.2 Global Single-Domain Antibody Therapeutics Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Single-Domain Antibody Therapeutics Sale Price by Type (2021-2026)
2.3 Single-Domain Antibody Therapeutics Segment by Administration Route
2.3.1 Subcutaneous Injection
2.3.2 Intravenous Injection
2.3.3 Other
2.3.4 Single-Domain Antibody Therapeutics Sales by Administration Route
2.3.4.1 Global Single-Domain Antibody Therapeutics Sales Market Share by Administration Route (2021-2026)
2.3.4.2 Global Single-Domain Antibody Therapeutics Revenue and Market Share by Administration Route (2021-2026)
2.3.4.3 Global Single-Domain Antibody Therapeutics Sale Price by Administration Route (2021-2026)
2.4 Single-Domain Antibody Therapeutics Segment by Sales Channels
2.4.1 Online Sales
2.4.2 Offline Sales
2.4.3 Single-Domain Antibody Therapeutics Sales by Sales Channels
2.4.3.1 Global Single-Domain Antibody Therapeutics Sales Market Share by Sales Channels (2021-2026)
2.4.3.2 Global Single-Domain Antibody Therapeutics Revenue and Market Share by Sales Channels (2021-2026)
2.4.3.3 Global Single-Domain Antibody Therapeutics Sale Price by Sales Channels (2021-2026)
2.5 Single-Domain Antibody Therapeutics Segment by Application
2.5.1 Hospital
2.5.2 Clinic
2.5.3 Others
2.5.4 Single-Domain Antibody Therapeutics Sales by Application
2.5.4.1 Global Single-Domain Antibody Therapeutics Sale Market Share by Application (2021-2026)
2.5.4.2 Global Single-Domain Antibody Therapeutics Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Single-Domain Antibody Therapeutics Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Single-Domain Antibody Therapeutics Breakdown Data by Company
3.1.1 Global Single-Domain Antibody Therapeutics Annual Sales by Company (2021-2026)
3.1.2 Global Single-Domain Antibody Therapeutics Sales Market Share by Company (2021-2026)
3.2 Global Single-Domain Antibody Therapeutics Annual Revenue by Company (2021-2026)
3.2.1 Global Single-Domain Antibody Therapeutics Revenue by Company (2021-2026)
3.2.2 Global Single-Domain Antibody Therapeutics Revenue Market Share by Company (2021-2026)
3.3 Global Single-Domain Antibody Therapeutics Sale Price by Company
3.4 Key Manufacturers Single-Domain Antibody Therapeutics Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Single-Domain Antibody Therapeutics Product Location Distribution
3.4.2 Players Single-Domain Antibody Therapeutics Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SINGLE-DOMAIN ANTIBODY THERAPEUTICS BY GEOGRAPHIC REGION
4.1 World Historic Single-Domain Antibody Therapeutics Market Size by Geographic Region (2021-2026)
4.1.1 Global Single-Domain Antibody Therapeutics Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Single-Domain Antibody Therapeutics Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Single-Domain Antibody Therapeutics Market Size by Country/Region (2021-2026)
4.2.1 Global Single-Domain Antibody Therapeutics Annual Sales by Country/Region (2021-2026)
4.2.2 Global Single-Domain Antibody Therapeutics Annual Revenue by Country/Region (2021-2026)
4.3 Americas Single-Domain Antibody Therapeutics Sales Growth
4.4 APAC Single-Domain Antibody Therapeutics Sales Growth
4.5 Europe Single-Domain Antibody Therapeutics Sales Growth
4.6 Middle East & Africa Single-Domain Antibody Therapeutics Sales Growth
5 AMERICAS
5.1 Americas Single-Domain Antibody Therapeutics Sales by Country
5.1.1 Americas Single-Domain Antibody Therapeutics Sales by Country (2021-2026)
5.1.2 Americas Single-Domain Antibody Therapeutics Revenue by Country (2021-2026)
5.2 Americas Single-Domain Antibody Therapeutics Sales by Type (2021-2026)
5.3 Americas Single-Domain Antibody Therapeutics Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Single-Domain Antibody Therapeutics Sales by Region
6.1.1 APAC Single-Domain Antibody Therapeutics Sales by Region (2021-2026)
6.1.2 APAC Single-Domain Antibody Therapeutics Revenue by Region (2021-2026)
6.2 APAC Single-Domain Antibody Therapeutics Sales by Type (2021-2026)
6.3 APAC Single-Domain Antibody Therapeutics Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Single-Domain Antibody Therapeutics by Country
7.1.1 Europe Single-Domain Antibody Therapeutics Sales by Country (2021-2026)
7.1.2 Europe Single-Domain Antibody Therapeutics Revenue by Country (2021-2026)
7.2 Europe Single-Domain Antibody Therapeutics Sales by Type (2021-2026)
7.3 Europe Single-Domain Antibody Therapeutics Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Single-Domain Antibody Therapeutics by Country
8.1.1 Middle East & Africa Single-Domain Antibody Therapeutics Sales by Country (2021-2026)
8.1.2 Middle East & Africa Single-Domain Antibody Therapeutics Revenue by Country (2021-2026)
8.2 Middle East & Africa Single-Domain Antibody Therapeutics Sales by Type (2021-2026)
8.3 Middle East & Africa Single-Domain Antibody Therapeutics Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Single-Domain Antibody Therapeutics
10.3 Manufacturing Process Analysis of Single-Domain Antibody Therapeutics
10.4 Industry Chain Structure of Single-Domain Antibody Therapeutics
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Single-Domain Antibody Therapeutics Distributors
11.3 Single-Domain Antibody Therapeutics Customer
12 WORLD FORECAST REVIEW FOR SINGLE-DOMAIN ANTIBODY THERAPEUTICS BY GEOGRAPHIC REGION
12.1 Global Single-Domain Antibody Therapeutics Market Size Forecast by Region
12.1.1 Global Single-Domain Antibody Therapeutics Forecast by Region (2027-2032)
12.1.2 Global Single-Domain Antibody Therapeutics Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Single-Domain Antibody Therapeutics Forecast by Type (2027-2032)
12.7 Global Single-Domain Antibody Therapeutics Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Single-Domain Antibody Therapeutics Product Portfolios and Specifications
13.1.3 Sanofi Single-Domain Antibody Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 Taisho Pharmaceutical
13.2.1 Taisho Pharmaceutical Company Information
13.2.2 Taisho Pharmaceutical Single-Domain Antibody Therapeutics Product Portfolios and Specifications
13.2.3 Taisho Pharmaceutical Single-Domain Antibody Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Taisho Pharmaceutical Main Business Overview
13.2.5 Taisho Pharmaceutical Latest Developments
13.3 Alphamab Oncology
13.3.1 Alphamab Oncology Company Information
13.3.2 Alphamab Oncology Single-Domain Antibody Therapeutics Product Portfolios and Specifications
13.3.3 Alphamab Oncology Single-Domain Antibody Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Alphamab Oncology Main Business Overview
13.3.5 Alphamab Oncology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Single-Domain Antibody Therapeutics Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Single-Domain Antibody Therapeutics by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Single-Domain Antibody Therapeutics by Country/Region, 2021, 2025 & 2032
2.2 Single-Domain Antibody Therapeutics Segment by Type
2.2.1 Cablivi
2.2.2 Nanozora
2.2.3 Envafolimab
2.2.4 Single-Domain Antibody Therapeutics Sales by Type
2.2.4.1 Global Single-Domain Antibody Therapeutics Sales Market Share by Type (2021-2026)
2.2.4.2 Global Single-Domain Antibody Therapeutics Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Single-Domain Antibody Therapeutics Sale Price by Type (2021-2026)
2.3 Single-Domain Antibody Therapeutics Segment by Administration Route
2.3.1 Subcutaneous Injection
2.3.2 Intravenous Injection
2.3.3 Other
2.3.4 Single-Domain Antibody Therapeutics Sales by Administration Route
2.3.4.1 Global Single-Domain Antibody Therapeutics Sales Market Share by Administration Route (2021-2026)
2.3.4.2 Global Single-Domain Antibody Therapeutics Revenue and Market Share by Administration Route (2021-2026)
2.3.4.3 Global Single-Domain Antibody Therapeutics Sale Price by Administration Route (2021-2026)
2.4 Single-Domain Antibody Therapeutics Segment by Sales Channels
2.4.1 Online Sales
2.4.2 Offline Sales
2.4.3 Single-Domain Antibody Therapeutics Sales by Sales Channels
2.4.3.1 Global Single-Domain Antibody Therapeutics Sales Market Share by Sales Channels (2021-2026)
2.4.3.2 Global Single-Domain Antibody Therapeutics Revenue and Market Share by Sales Channels (2021-2026)
2.4.3.3 Global Single-Domain Antibody Therapeutics Sale Price by Sales Channels (2021-2026)
2.5 Single-Domain Antibody Therapeutics Segment by Application
2.5.1 Hospital
2.5.2 Clinic
2.5.3 Others
2.5.4 Single-Domain Antibody Therapeutics Sales by Application
2.5.4.1 Global Single-Domain Antibody Therapeutics Sale Market Share by Application (2021-2026)
2.5.4.2 Global Single-Domain Antibody Therapeutics Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Single-Domain Antibody Therapeutics Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Single-Domain Antibody Therapeutics Breakdown Data by Company
3.1.1 Global Single-Domain Antibody Therapeutics Annual Sales by Company (2021-2026)
3.1.2 Global Single-Domain Antibody Therapeutics Sales Market Share by Company (2021-2026)
3.2 Global Single-Domain Antibody Therapeutics Annual Revenue by Company (2021-2026)
3.2.1 Global Single-Domain Antibody Therapeutics Revenue by Company (2021-2026)
3.2.2 Global Single-Domain Antibody Therapeutics Revenue Market Share by Company (2021-2026)
3.3 Global Single-Domain Antibody Therapeutics Sale Price by Company
3.4 Key Manufacturers Single-Domain Antibody Therapeutics Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Single-Domain Antibody Therapeutics Product Location Distribution
3.4.2 Players Single-Domain Antibody Therapeutics Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SINGLE-DOMAIN ANTIBODY THERAPEUTICS BY GEOGRAPHIC REGION
4.1 World Historic Single-Domain Antibody Therapeutics Market Size by Geographic Region (2021-2026)
4.1.1 Global Single-Domain Antibody Therapeutics Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Single-Domain Antibody Therapeutics Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Single-Domain Antibody Therapeutics Market Size by Country/Region (2021-2026)
4.2.1 Global Single-Domain Antibody Therapeutics Annual Sales by Country/Region (2021-2026)
4.2.2 Global Single-Domain Antibody Therapeutics Annual Revenue by Country/Region (2021-2026)
4.3 Americas Single-Domain Antibody Therapeutics Sales Growth
4.4 APAC Single-Domain Antibody Therapeutics Sales Growth
4.5 Europe Single-Domain Antibody Therapeutics Sales Growth
4.6 Middle East & Africa Single-Domain Antibody Therapeutics Sales Growth
5 AMERICAS
5.1 Americas Single-Domain Antibody Therapeutics Sales by Country
5.1.1 Americas Single-Domain Antibody Therapeutics Sales by Country (2021-2026)
5.1.2 Americas Single-Domain Antibody Therapeutics Revenue by Country (2021-2026)
5.2 Americas Single-Domain Antibody Therapeutics Sales by Type (2021-2026)
5.3 Americas Single-Domain Antibody Therapeutics Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Single-Domain Antibody Therapeutics Sales by Region
6.1.1 APAC Single-Domain Antibody Therapeutics Sales by Region (2021-2026)
6.1.2 APAC Single-Domain Antibody Therapeutics Revenue by Region (2021-2026)
6.2 APAC Single-Domain Antibody Therapeutics Sales by Type (2021-2026)
6.3 APAC Single-Domain Antibody Therapeutics Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Single-Domain Antibody Therapeutics by Country
7.1.1 Europe Single-Domain Antibody Therapeutics Sales by Country (2021-2026)
7.1.2 Europe Single-Domain Antibody Therapeutics Revenue by Country (2021-2026)
7.2 Europe Single-Domain Antibody Therapeutics Sales by Type (2021-2026)
7.3 Europe Single-Domain Antibody Therapeutics Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Single-Domain Antibody Therapeutics by Country
8.1.1 Middle East & Africa Single-Domain Antibody Therapeutics Sales by Country (2021-2026)
8.1.2 Middle East & Africa Single-Domain Antibody Therapeutics Revenue by Country (2021-2026)
8.2 Middle East & Africa Single-Domain Antibody Therapeutics Sales by Type (2021-2026)
8.3 Middle East & Africa Single-Domain Antibody Therapeutics Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Single-Domain Antibody Therapeutics
10.3 Manufacturing Process Analysis of Single-Domain Antibody Therapeutics
10.4 Industry Chain Structure of Single-Domain Antibody Therapeutics
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Single-Domain Antibody Therapeutics Distributors
11.3 Single-Domain Antibody Therapeutics Customer
12 WORLD FORECAST REVIEW FOR SINGLE-DOMAIN ANTIBODY THERAPEUTICS BY GEOGRAPHIC REGION
12.1 Global Single-Domain Antibody Therapeutics Market Size Forecast by Region
12.1.1 Global Single-Domain Antibody Therapeutics Forecast by Region (2027-2032)
12.1.2 Global Single-Domain Antibody Therapeutics Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Single-Domain Antibody Therapeutics Forecast by Type (2027-2032)
12.7 Global Single-Domain Antibody Therapeutics Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Single-Domain Antibody Therapeutics Product Portfolios and Specifications
13.1.3 Sanofi Single-Domain Antibody Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 Taisho Pharmaceutical
13.2.1 Taisho Pharmaceutical Company Information
13.2.2 Taisho Pharmaceutical Single-Domain Antibody Therapeutics Product Portfolios and Specifications
13.2.3 Taisho Pharmaceutical Single-Domain Antibody Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Taisho Pharmaceutical Main Business Overview
13.2.5 Taisho Pharmaceutical Latest Developments
13.3 Alphamab Oncology
13.3.1 Alphamab Oncology Company Information
13.3.2 Alphamab Oncology Single-Domain Antibody Therapeutics Product Portfolios and Specifications
13.3.3 Alphamab Oncology Single-Domain Antibody Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Alphamab Oncology Main Business Overview
13.3.5 Alphamab Oncology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Single-Domain Antibody Therapeutics Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Single-Domain Antibody Therapeutics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Cablivi
Table 4. Major Players of Nanozora
Table 5. Major Players of Envafolimab
Table 6. Global Single-Domain Antibody Therapeutics Sales by Type (2021-2026) & (K Units)
Table 7. Global Single-Domain Antibody Therapeutics Sales Market Share by Type (2021-2026)
Table 8. Global Single-Domain Antibody Therapeutics Revenue by Type (2021-2026) & ($ million)
Table 9. Global Single-Domain Antibody Therapeutics Revenue Market Share by Type (2021-2026)
Table 10. Global Single-Domain Antibody Therapeutics Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Major Players of Subcutaneous Injection
Table 12. Major Players of Intravenous Injection
Table 13. Major Players of Other
Table 14. Global Single-Domain Antibody Therapeutics Sales by Administration Route (2021-2026) & (K Units)
Table 15. Global Single-Domain Antibody Therapeutics Sales Market Share by Administration Route (2021-2026)
Table 16. Global Single-Domain Antibody Therapeutics Revenue by Administration Route (2021-2026) & ($ million)
Table 17. Global Single-Domain Antibody Therapeutics Revenue Market Share by Administration Route (2021-2026)
Table 18. Global Single-Domain Antibody Therapeutics Sale Price by Administration Route (2021-2026) & (US$/Unit)
Table 19. Major Players of Online Sales
Table 20. Major Players of Offline Sales
Table 21. Global Single-Domain Antibody Therapeutics Sales by Sales Channels (2021-2026) & (K Units)
Table 22. Global Single-Domain Antibody Therapeutics Sales Market Share by Sales Channels (2021-2026)
Table 23. Global Single-Domain Antibody Therapeutics Revenue by Sales Channels (2021-2026) & ($ million)
Table 24. Global Single-Domain Antibody Therapeutics Revenue Market Share by Sales Channels (2021-2026)
Table 25. Global Single-Domain Antibody Therapeutics Sale Price by Sales Channels (2021-2026) & (US$/Unit)
Table 26. Global Single-Domain Antibody Therapeutics Sale by Application (2021-2026) & (K Units)
Table 27. Global Single-Domain Antibody Therapeutics Sale Market Share by Application (2021-2026)
Table 28. Global Single-Domain Antibody Therapeutics Revenue by Application (2021-2026) & ($ million)
Table 29. Global Single-Domain Antibody Therapeutics Revenue Market Share by Application (2021-2026)
Table 30. Global Single-Domain Antibody Therapeutics Sale Price by Application (2021-2026) & (US$/Unit)
Table 31. Global Single-Domain Antibody Therapeutics Sales by Company (2021-2026) & (K Units)
Table 32. Global Single-Domain Antibody Therapeutics Sales Market Share by Company (2021-2026)
Table 33. Global Single-Domain Antibody Therapeutics Revenue by Company (2021-2026) & ($ millions)
Table 34. Global Single-Domain Antibody Therapeutics Revenue Market Share by Company (2021-2026)
Table 35. Global Single-Domain Antibody Therapeutics Sale Price by Company (2021-2026) & (US$/Unit)
Table 36. Key Manufacturers Single-Domain Antibody Therapeutics Producing Area Distribution and Sales Area
Table 37. Players Single-Domain Antibody Therapeutics Products Offered
Table 38. Single-Domain Antibody Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 39. New Products and Potential Entrants
Table 40. Market M&A Activity & Strategy
Table 41. Global Single-Domain Antibody Therapeutics Sales by Geographic Region (2021-2026) & (K Units)
Table 42. Global Single-Domain Antibody Therapeutics Sales Market Share Geographic Region (2021-2026)
Table 43. Global Single-Domain Antibody Therapeutics Revenue by Geographic Region (2021-2026) & ($ millions)
Table 44. Global Single-Domain Antibody Therapeutics Revenue Market Share by Geographic Region (2021-2026)
Table 45. Global Single-Domain Antibody Therapeutics Sales by Country/Region (2021-2026) & (K Units)
Table 46. Global Single-Domain Antibody Therapeutics Sales Market Share by Country/Region (2021-2026)
Table 47. Global Single-Domain Antibody Therapeutics Revenue by Country/Region (2021-2026) & ($ millions)
Table 48. Global Single-Domain Antibody Therapeutics Revenue Market Share by Country/Region (2021-2026)
Table 49. Americas Single-Domain Antibody Therapeutics Sales by Country (2021-2026) & (K Units)
Table 50. Americas Single-Domain Antibody Therapeutics Sales Market Share by Country (2021-2026)
Table 51. Americas Single-Domain Antibody Therapeutics Revenue by Country (2021-2026) & ($ millions)
Table 52. Americas Single-Domain Antibody Therapeutics Sales by Type (2021-2026) & (K Units)
Table 53. Americas Single-Domain Antibody Therapeutics Sales by Application (2021-2026) & (K Units)
Table 54. APAC Single-Domain Antibody Therapeutics Sales by Region (2021-2026) & (K Units)
Table 55. APAC Single-Domain Antibody Therapeutics Sales Market Share by Region (2021-2026)
Table 56. APAC Single-Domain Antibody Therapeutics Revenue by Region (2021-2026) & ($ millions)
Table 57. APAC Single-Domain Antibody Therapeutics Sales by Type (2021-2026) & (K Units)
Table 58. APAC Single-Domain Antibody Therapeutics Sales by Application (2021-2026) & (K Units)
Table 59. Europe Single-Domain Antibody Therapeutics Sales by Country (2021-2026) & (K Units)
Table 60. Europe Single-Domain Antibody Therapeutics Revenue by Country (2021-2026) & ($ millions)
Table 61. Europe Single-Domain Antibody Therapeutics Sales by Type (2021-2026) & (K Units)
Table 62. Europe Single-Domain Antibody Therapeutics Sales by Application (2021-2026) & (K Units)
Table 63. Middle East & Africa Single-Domain Antibody Therapeutics Sales by Country (2021-2026) & (K Units)
Table 64. Middle East & Africa Single-Domain Antibody Therapeutics Revenue Market Share by Country (2021-2026)
Table 65. Middle East & Africa Single-Domain Antibody Therapeutics Sales by Type (2021-2026) & (K Units)
Table 66. Middle East & Africa Single-Domain Antibody Therapeutics Sales by Application (2021-2026) & (K Units)
Table 67. Key Market Drivers & Growth Opportunities of Single-Domain Antibody Therapeutics
Table 68. Key Market Challenges & Risks of Single-Domain Antibody Therapeutics
Table 69. Key Industry Trends of Single-Domain Antibody Therapeutics
Table 70. Single-Domain Antibody Therapeutics Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Single-Domain Antibody Therapeutics Distributors List
Table 73. Single-Domain Antibody Therapeutics Customer List
Table 74. Global Single-Domain Antibody Therapeutics Sales Forecast by Region (2027-2032) & (K Units)
Table 75. Global Single-Domain Antibody Therapeutics Revenue Forecast by Region (2027-2032) & ($ millions)
Table 76. Americas Single-Domain Antibody Therapeutics Sales Forecast by Country (2027-2032) & (K Units)
Table 77. Americas Single-Domain Antibody Therapeutics Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. APAC Single-Domain Antibody Therapeutics Sales Forecast by Region (2027-2032) & (K Units)
Table 79. APAC Single-Domain Antibody Therapeutics Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 80. Europe Single-Domain Antibody Therapeutics Sales Forecast by Country (2027-2032) & (K Units)
Table 81. Europe Single-Domain Antibody Therapeutics Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. Middle East & Africa Single-Domain Antibody Therapeutics Sales Forecast by Country (2027-2032) & (K Units)
Table 83. Middle East & Africa Single-Domain Antibody Therapeutics Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Global Single-Domain Antibody Therapeutics Sales Forecast by Type (2027-2032) & (K Units)
Table 85. Global Single-Domain Antibody Therapeutics Revenue Forecast by Type (2027-2032) & ($ millions)
Table 86. Global Single-Domain Antibody Therapeutics Sales Forecast by Application (2027-2032) & (K Units)
Table 87. Global Single-Domain Antibody Therapeutics Revenue Forecast by Application (2027-2032) & ($ millions)
Table 88. Sanofi Basic Information, Single-Domain Antibody Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 89. Sanofi Single-Domain Antibody Therapeutics Product Portfolios and Specifications
Table 90. Sanofi Single-Domain Antibody Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Sanofi Main Business
Table 92. Sanofi Latest Developments
Table 93. Taisho Pharmaceutical Basic Information, Single-Domain Antibody Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 94. Taisho Pharmaceutical Single-Domain Antibody Therapeutics Product Portfolios and Specifications
Table 95. Taisho Pharmaceutical Single-Domain Antibody Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Taisho Pharmaceutical Main Business
Table 97. Taisho Pharmaceutical Latest Developments
Table 98. Alphamab Oncology Basic Information, Single-Domain Antibody Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 99. Alphamab Oncology Single-Domain Antibody Therapeutics Product Portfolios and Specifications
Table 100. Alphamab Oncology Single-Domain Antibody Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Alphamab Oncology Main Business
Table 102. Alphamab Oncology Latest Developments
Table 1. Single-Domain Antibody Therapeutics Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Single-Domain Antibody Therapeutics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Cablivi
Table 4. Major Players of Nanozora
Table 5. Major Players of Envafolimab
Table 6. Global Single-Domain Antibody Therapeutics Sales by Type (2021-2026) & (K Units)
Table 7. Global Single-Domain Antibody Therapeutics Sales Market Share by Type (2021-2026)
Table 8. Global Single-Domain Antibody Therapeutics Revenue by Type (2021-2026) & ($ million)
Table 9. Global Single-Domain Antibody Therapeutics Revenue Market Share by Type (2021-2026)
Table 10. Global Single-Domain Antibody Therapeutics Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Major Players of Subcutaneous Injection
Table 12. Major Players of Intravenous Injection
Table 13. Major Players of Other
Table 14. Global Single-Domain Antibody Therapeutics Sales by Administration Route (2021-2026) & (K Units)
Table 15. Global Single-Domain Antibody Therapeutics Sales Market Share by Administration Route (2021-2026)
Table 16. Global Single-Domain Antibody Therapeutics Revenue by Administration Route (2021-2026) & ($ million)
Table 17. Global Single-Domain Antibody Therapeutics Revenue Market Share by Administration Route (2021-2026)
Table 18. Global Single-Domain Antibody Therapeutics Sale Price by Administration Route (2021-2026) & (US$/Unit)
Table 19. Major Players of Online Sales
Table 20. Major Players of Offline Sales
Table 21. Global Single-Domain Antibody Therapeutics Sales by Sales Channels (2021-2026) & (K Units)
Table 22. Global Single-Domain Antibody Therapeutics Sales Market Share by Sales Channels (2021-2026)
Table 23. Global Single-Domain Antibody Therapeutics Revenue by Sales Channels (2021-2026) & ($ million)
Table 24. Global Single-Domain Antibody Therapeutics Revenue Market Share by Sales Channels (2021-2026)
Table 25. Global Single-Domain Antibody Therapeutics Sale Price by Sales Channels (2021-2026) & (US$/Unit)
Table 26. Global Single-Domain Antibody Therapeutics Sale by Application (2021-2026) & (K Units)
Table 27. Global Single-Domain Antibody Therapeutics Sale Market Share by Application (2021-2026)
Table 28. Global Single-Domain Antibody Therapeutics Revenue by Application (2021-2026) & ($ million)
Table 29. Global Single-Domain Antibody Therapeutics Revenue Market Share by Application (2021-2026)
Table 30. Global Single-Domain Antibody Therapeutics Sale Price by Application (2021-2026) & (US$/Unit)
Table 31. Global Single-Domain Antibody Therapeutics Sales by Company (2021-2026) & (K Units)
Table 32. Global Single-Domain Antibody Therapeutics Sales Market Share by Company (2021-2026)
Table 33. Global Single-Domain Antibody Therapeutics Revenue by Company (2021-2026) & ($ millions)
Table 34. Global Single-Domain Antibody Therapeutics Revenue Market Share by Company (2021-2026)
Table 35. Global Single-Domain Antibody Therapeutics Sale Price by Company (2021-2026) & (US$/Unit)
Table 36. Key Manufacturers Single-Domain Antibody Therapeutics Producing Area Distribution and Sales Area
Table 37. Players Single-Domain Antibody Therapeutics Products Offered
Table 38. Single-Domain Antibody Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 39. New Products and Potential Entrants
Table 40. Market M&A Activity & Strategy
Table 41. Global Single-Domain Antibody Therapeutics Sales by Geographic Region (2021-2026) & (K Units)
Table 42. Global Single-Domain Antibody Therapeutics Sales Market Share Geographic Region (2021-2026)
Table 43. Global Single-Domain Antibody Therapeutics Revenue by Geographic Region (2021-2026) & ($ millions)
Table 44. Global Single-Domain Antibody Therapeutics Revenue Market Share by Geographic Region (2021-2026)
Table 45. Global Single-Domain Antibody Therapeutics Sales by Country/Region (2021-2026) & (K Units)
Table 46. Global Single-Domain Antibody Therapeutics Sales Market Share by Country/Region (2021-2026)
Table 47. Global Single-Domain Antibody Therapeutics Revenue by Country/Region (2021-2026) & ($ millions)
Table 48. Global Single-Domain Antibody Therapeutics Revenue Market Share by Country/Region (2021-2026)
Table 49. Americas Single-Domain Antibody Therapeutics Sales by Country (2021-2026) & (K Units)
Table 50. Americas Single-Domain Antibody Therapeutics Sales Market Share by Country (2021-2026)
Table 51. Americas Single-Domain Antibody Therapeutics Revenue by Country (2021-2026) & ($ millions)
Table 52. Americas Single-Domain Antibody Therapeutics Sales by Type (2021-2026) & (K Units)
Table 53. Americas Single-Domain Antibody Therapeutics Sales by Application (2021-2026) & (K Units)
Table 54. APAC Single-Domain Antibody Therapeutics Sales by Region (2021-2026) & (K Units)
Table 55. APAC Single-Domain Antibody Therapeutics Sales Market Share by Region (2021-2026)
Table 56. APAC Single-Domain Antibody Therapeutics Revenue by Region (2021-2026) & ($ millions)
Table 57. APAC Single-Domain Antibody Therapeutics Sales by Type (2021-2026) & (K Units)
Table 58. APAC Single-Domain Antibody Therapeutics Sales by Application (2021-2026) & (K Units)
Table 59. Europe Single-Domain Antibody Therapeutics Sales by Country (2021-2026) & (K Units)
Table 60. Europe Single-Domain Antibody Therapeutics Revenue by Country (2021-2026) & ($ millions)
Table 61. Europe Single-Domain Antibody Therapeutics Sales by Type (2021-2026) & (K Units)
Table 62. Europe Single-Domain Antibody Therapeutics Sales by Application (2021-2026) & (K Units)
Table 63. Middle East & Africa Single-Domain Antibody Therapeutics Sales by Country (2021-2026) & (K Units)
Table 64. Middle East & Africa Single-Domain Antibody Therapeutics Revenue Market Share by Country (2021-2026)
Table 65. Middle East & Africa Single-Domain Antibody Therapeutics Sales by Type (2021-2026) & (K Units)
Table 66. Middle East & Africa Single-Domain Antibody Therapeutics Sales by Application (2021-2026) & (K Units)
Table 67. Key Market Drivers & Growth Opportunities of Single-Domain Antibody Therapeutics
Table 68. Key Market Challenges & Risks of Single-Domain Antibody Therapeutics
Table 69. Key Industry Trends of Single-Domain Antibody Therapeutics
Table 70. Single-Domain Antibody Therapeutics Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Single-Domain Antibody Therapeutics Distributors List
Table 73. Single-Domain Antibody Therapeutics Customer List
Table 74. Global Single-Domain Antibody Therapeutics Sales Forecast by Region (2027-2032) & (K Units)
Table 75. Global Single-Domain Antibody Therapeutics Revenue Forecast by Region (2027-2032) & ($ millions)
Table 76. Americas Single-Domain Antibody Therapeutics Sales Forecast by Country (2027-2032) & (K Units)
Table 77. Americas Single-Domain Antibody Therapeutics Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. APAC Single-Domain Antibody Therapeutics Sales Forecast by Region (2027-2032) & (K Units)
Table 79. APAC Single-Domain Antibody Therapeutics Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 80. Europe Single-Domain Antibody Therapeutics Sales Forecast by Country (2027-2032) & (K Units)
Table 81. Europe Single-Domain Antibody Therapeutics Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. Middle East & Africa Single-Domain Antibody Therapeutics Sales Forecast by Country (2027-2032) & (K Units)
Table 83. Middle East & Africa Single-Domain Antibody Therapeutics Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Global Single-Domain Antibody Therapeutics Sales Forecast by Type (2027-2032) & (K Units)
Table 85. Global Single-Domain Antibody Therapeutics Revenue Forecast by Type (2027-2032) & ($ millions)
Table 86. Global Single-Domain Antibody Therapeutics Sales Forecast by Application (2027-2032) & (K Units)
Table 87. Global Single-Domain Antibody Therapeutics Revenue Forecast by Application (2027-2032) & ($ millions)
Table 88. Sanofi Basic Information, Single-Domain Antibody Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 89. Sanofi Single-Domain Antibody Therapeutics Product Portfolios and Specifications
Table 90. Sanofi Single-Domain Antibody Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Sanofi Main Business
Table 92. Sanofi Latest Developments
Table 93. Taisho Pharmaceutical Basic Information, Single-Domain Antibody Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 94. Taisho Pharmaceutical Single-Domain Antibody Therapeutics Product Portfolios and Specifications
Table 95. Taisho Pharmaceutical Single-Domain Antibody Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Taisho Pharmaceutical Main Business
Table 97. Taisho Pharmaceutical Latest Developments
Table 98. Alphamab Oncology Basic Information, Single-Domain Antibody Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 99. Alphamab Oncology Single-Domain Antibody Therapeutics Product Portfolios and Specifications
Table 100. Alphamab Oncology Single-Domain Antibody Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Alphamab Oncology Main Business
Table 102. Alphamab Oncology Latest Developments
LIST OF FIGURES
Figure 1. Picture of Single-Domain Antibody Therapeutics
Figure 2. Single-Domain Antibody Therapeutics Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Single-Domain Antibody Therapeutics Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Single-Domain Antibody Therapeutics Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Single-Domain Antibody Therapeutics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Single-Domain Antibody Therapeutics Sales Market Share by Country/Region (2025)
Figure 10. Single-Domain Antibody Therapeutics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Cablivi
Figure 12. Product Picture of Nanozora
Figure 13. Product Picture of Envafolimab
Figure 14. Global Single-Domain Antibody Therapeutics Sales Market Share by Type in 2026
Figure 15. Global Single-Domain Antibody Therapeutics Revenue Market Share by Type (2021-2026)
Figure 16. Product Picture of Subcutaneous Injection
Figure 17. Product Picture of Intravenous Injection
Figure 18. Product Picture of Other
Figure 19. Global Single-Domain Antibody Therapeutics Sales Market Share by Administration Route in 2026
Figure 20. Global Single-Domain Antibody Therapeutics Revenue Market Share by Administration Route (2021-2026)
Figure 21. Product Picture of Online Sales
Figure 22. Product Picture of Offline Sales
Figure 23. Global Single-Domain Antibody Therapeutics Sales Market Share by Sales Channels in 2026
Figure 24. Global Single-Domain Antibody Therapeutics Revenue Market Share by Sales Channels (2021-2026)
Figure 25. Single-Domain Antibody Therapeutics Consumed in Hospital
Figure 26. Global Single-Domain Antibody Therapeutics Market: Hospital (2021-2026) & (K Units)
Figure 27. Single-Domain Antibody Therapeutics Consumed in Clinic
Figure 28. Global Single-Domain Antibody Therapeutics Market: Clinic (2021-2026) & (K Units)
Figure 29. Single-Domain Antibody Therapeutics Consumed in Others
Figure 30. Global Single-Domain Antibody Therapeutics Market: Others (2021-2026) & (K Units)
Figure 31. Global Single-Domain Antibody Therapeutics Sale Market Share by Application (2025)
Figure 32. Global Single-Domain Antibody Therapeutics Revenue Market Share by Application in 2025
Figure 33. Single-Domain Antibody Therapeutics Sales by Company in 2025 (K Units)
Figure 34. Global Single-Domain Antibody Therapeutics Sales Market Share by Company in 2025
Figure 35. Single-Domain Antibody Therapeutics Revenue by Company in 2025 ($ millions)
Figure 36. Global Single-Domain Antibody Therapeutics Revenue Market Share by Company in 2025
Figure 37. Global Single-Domain Antibody Therapeutics Sales Market Share by Geographic Region (2021-2026)
Figure 38. Global Single-Domain Antibody Therapeutics Revenue Market Share by Geographic Region in 2025
Figure 39. Americas Single-Domain Antibody Therapeutics Sales 2021-2026 (K Units)
Figure 40. Americas Single-Domain Antibody Therapeutics Revenue 2021-2026 ($ millions)
Figure 41. APAC Single-Domain Antibody Therapeutics Sales 2021-2026 (K Units)
Figure 42. APAC Single-Domain Antibody Therapeutics Revenue 2021-2026 ($ millions)
Figure 43. Europe Single-Domain Antibody Therapeutics Sales 2021-2026 (K Units)
Figure 44. Europe Single-Domain Antibody Therapeutics Revenue 2021-2026 ($ millions)
Figure 45. Middle East & Africa Single-Domain Antibody Therapeutics Sales 2021-2026 (K Units)
Figure 46. Middle East & Africa Single-Domain Antibody Therapeutics Revenue 2021-2026 ($ millions)
Figure 47. Americas Single-Domain Antibody Therapeutics Sales Market Share by Country in 2025
Figure 48. Americas Single-Domain Antibody Therapeutics Revenue Market Share by Country (2021-2026)
Figure 49. Americas Single-Domain Antibody Therapeutics Sales Market Share by Type (2021-2026)
Figure 50. Americas Single-Domain Antibody Therapeutics Sales Market Share by Application (2021-2026)
Figure 51. United States Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 52. Canada Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 53. Mexico Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 54. Brazil Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 55. APAC Single-Domain Antibody Therapeutics Sales Market Share by Region in 2025
Figure 56. APAC Single-Domain Antibody Therapeutics Revenue Market Share by Region (2021-2026)
Figure 57. APAC Single-Domain Antibody Therapeutics Sales Market Share by Type (2021-2026)
Figure 58. APAC Single-Domain Antibody Therapeutics Sales Market Share by Application (2021-2026)
Figure 59. China Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 60. Japan Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 61. South Korea Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 62. Southeast Asia Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 63. India Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 64. Australia Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 65. China Taiwan Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 66. Europe Single-Domain Antibody Therapeutics Sales Market Share by Country in 2025
Figure 67. Europe Single-Domain Antibody Therapeutics Revenue Market Share by Country (2021-2026)
Figure 68. Europe Single-Domain Antibody Therapeutics Sales Market Share by Type (2021-2026)
Figure 69. Europe Single-Domain Antibody Therapeutics Sales Market Share by Application (2021-2026)
Figure 70. Germany Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 71. France Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 72. UK Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 73. Italy Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 74. Russia Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 75. Middle East & Africa Single-Domain Antibody Therapeutics Sales Market Share by Country (2021-2026)
Figure 76. Middle East & Africa Single-Domain Antibody Therapeutics Sales Market Share by Type (2021-2026)
Figure 77. Middle East & Africa Single-Domain Antibody Therapeutics Sales Market Share by Application (2021-2026)
Figure 78. Egypt Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 79. South Africa Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 80. Israel Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 81. Turkey Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 82. GCC Countries Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 83. Manufacturing Cost Structure Analysis of Single-Domain Antibody Therapeutics in 2026
Figure 84. Manufacturing Process Analysis of Single-Domain Antibody Therapeutics
Figure 85. Industry Chain Structure of Single-Domain Antibody Therapeutics
Figure 86. Channels of Distribution
Figure 87. Global Single-Domain Antibody Therapeutics Sales Market Forecast by Region (2027-2032)
Figure 88. Global Single-Domain Antibody Therapeutics Revenue Market Share Forecast by Region (2027-2032)
Figure 89. Global Single-Domain Antibody Therapeutics Sales Market Share Forecast by Type (2027-2032)
Figure 90. Global Single-Domain Antibody Therapeutics Revenue Market Share Forecast by Type (2027-2032)
Figure 91. Global Single-Domain Antibody Therapeutics Sales Market Share Forecast by Application (2027-2032)
Figure 92. Global Single-Domain Antibody Therapeutics Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Single-Domain Antibody Therapeutics
Figure 2. Single-Domain Antibody Therapeutics Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Single-Domain Antibody Therapeutics Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Single-Domain Antibody Therapeutics Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Single-Domain Antibody Therapeutics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Single-Domain Antibody Therapeutics Sales Market Share by Country/Region (2025)
Figure 10. Single-Domain Antibody Therapeutics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Cablivi
Figure 12. Product Picture of Nanozora
Figure 13. Product Picture of Envafolimab
Figure 14. Global Single-Domain Antibody Therapeutics Sales Market Share by Type in 2026
Figure 15. Global Single-Domain Antibody Therapeutics Revenue Market Share by Type (2021-2026)
Figure 16. Product Picture of Subcutaneous Injection
Figure 17. Product Picture of Intravenous Injection
Figure 18. Product Picture of Other
Figure 19. Global Single-Domain Antibody Therapeutics Sales Market Share by Administration Route in 2026
Figure 20. Global Single-Domain Antibody Therapeutics Revenue Market Share by Administration Route (2021-2026)
Figure 21. Product Picture of Online Sales
Figure 22. Product Picture of Offline Sales
Figure 23. Global Single-Domain Antibody Therapeutics Sales Market Share by Sales Channels in 2026
Figure 24. Global Single-Domain Antibody Therapeutics Revenue Market Share by Sales Channels (2021-2026)
Figure 25. Single-Domain Antibody Therapeutics Consumed in Hospital
Figure 26. Global Single-Domain Antibody Therapeutics Market: Hospital (2021-2026) & (K Units)
Figure 27. Single-Domain Antibody Therapeutics Consumed in Clinic
Figure 28. Global Single-Domain Antibody Therapeutics Market: Clinic (2021-2026) & (K Units)
Figure 29. Single-Domain Antibody Therapeutics Consumed in Others
Figure 30. Global Single-Domain Antibody Therapeutics Market: Others (2021-2026) & (K Units)
Figure 31. Global Single-Domain Antibody Therapeutics Sale Market Share by Application (2025)
Figure 32. Global Single-Domain Antibody Therapeutics Revenue Market Share by Application in 2025
Figure 33. Single-Domain Antibody Therapeutics Sales by Company in 2025 (K Units)
Figure 34. Global Single-Domain Antibody Therapeutics Sales Market Share by Company in 2025
Figure 35. Single-Domain Antibody Therapeutics Revenue by Company in 2025 ($ millions)
Figure 36. Global Single-Domain Antibody Therapeutics Revenue Market Share by Company in 2025
Figure 37. Global Single-Domain Antibody Therapeutics Sales Market Share by Geographic Region (2021-2026)
Figure 38. Global Single-Domain Antibody Therapeutics Revenue Market Share by Geographic Region in 2025
Figure 39. Americas Single-Domain Antibody Therapeutics Sales 2021-2026 (K Units)
Figure 40. Americas Single-Domain Antibody Therapeutics Revenue 2021-2026 ($ millions)
Figure 41. APAC Single-Domain Antibody Therapeutics Sales 2021-2026 (K Units)
Figure 42. APAC Single-Domain Antibody Therapeutics Revenue 2021-2026 ($ millions)
Figure 43. Europe Single-Domain Antibody Therapeutics Sales 2021-2026 (K Units)
Figure 44. Europe Single-Domain Antibody Therapeutics Revenue 2021-2026 ($ millions)
Figure 45. Middle East & Africa Single-Domain Antibody Therapeutics Sales 2021-2026 (K Units)
Figure 46. Middle East & Africa Single-Domain Antibody Therapeutics Revenue 2021-2026 ($ millions)
Figure 47. Americas Single-Domain Antibody Therapeutics Sales Market Share by Country in 2025
Figure 48. Americas Single-Domain Antibody Therapeutics Revenue Market Share by Country (2021-2026)
Figure 49. Americas Single-Domain Antibody Therapeutics Sales Market Share by Type (2021-2026)
Figure 50. Americas Single-Domain Antibody Therapeutics Sales Market Share by Application (2021-2026)
Figure 51. United States Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 52. Canada Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 53. Mexico Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 54. Brazil Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 55. APAC Single-Domain Antibody Therapeutics Sales Market Share by Region in 2025
Figure 56. APAC Single-Domain Antibody Therapeutics Revenue Market Share by Region (2021-2026)
Figure 57. APAC Single-Domain Antibody Therapeutics Sales Market Share by Type (2021-2026)
Figure 58. APAC Single-Domain Antibody Therapeutics Sales Market Share by Application (2021-2026)
Figure 59. China Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 60. Japan Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 61. South Korea Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 62. Southeast Asia Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 63. India Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 64. Australia Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 65. China Taiwan Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 66. Europe Single-Domain Antibody Therapeutics Sales Market Share by Country in 2025
Figure 67. Europe Single-Domain Antibody Therapeutics Revenue Market Share by Country (2021-2026)
Figure 68. Europe Single-Domain Antibody Therapeutics Sales Market Share by Type (2021-2026)
Figure 69. Europe Single-Domain Antibody Therapeutics Sales Market Share by Application (2021-2026)
Figure 70. Germany Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 71. France Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 72. UK Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 73. Italy Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 74. Russia Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 75. Middle East & Africa Single-Domain Antibody Therapeutics Sales Market Share by Country (2021-2026)
Figure 76. Middle East & Africa Single-Domain Antibody Therapeutics Sales Market Share by Type (2021-2026)
Figure 77. Middle East & Africa Single-Domain Antibody Therapeutics Sales Market Share by Application (2021-2026)
Figure 78. Egypt Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 79. South Africa Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 80. Israel Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 81. Turkey Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 82. GCC Countries Single-Domain Antibody Therapeutics Revenue Growth 2021-2026 ($ millions)
Figure 83. Manufacturing Cost Structure Analysis of Single-Domain Antibody Therapeutics in 2026
Figure 84. Manufacturing Process Analysis of Single-Domain Antibody Therapeutics
Figure 85. Industry Chain Structure of Single-Domain Antibody Therapeutics
Figure 86. Channels of Distribution
Figure 87. Global Single-Domain Antibody Therapeutics Sales Market Forecast by Region (2027-2032)
Figure 88. Global Single-Domain Antibody Therapeutics Revenue Market Share Forecast by Region (2027-2032)
Figure 89. Global Single-Domain Antibody Therapeutics Sales Market Share Forecast by Type (2027-2032)
Figure 90. Global Single-Domain Antibody Therapeutics Revenue Market Share Forecast by Type (2027-2032)
Figure 91. Global Single-Domain Antibody Therapeutics Sales Market Share Forecast by Application (2027-2032)
Figure 92. Global Single-Domain Antibody Therapeutics Revenue Market Share Forecast by Application (2027-2032)
